Company: IMNN
Filing Date: 2025-12-31
Form Type: 424B5
Source: 0001493152-25-029712
Chunk: 17

Company: Imunon, Inc.
Filing Date: 2025-12-31
Form: 424B5
Chunk 17
---
 us.

The following table shows the offering price, Placement Agents’ fees and proceeds, before expenses, to us, assuming the purchase of all the securities we are offering.

|                                  |     | Per Share and Accompanying Warrant |        |     | Per Pre-funded Warrant and Accompanying Warrant |        |     | Total |              |
|:---------------------------------|:----|:-----------------------------------|-------:|:----|:------------------------------------------------|-------:|:----|:------|-------------:|
| Offering price                   |     | $                                  | 3.6100 |     | $                                               | 3.6099 |     | $     | 7,000,040.63 |
| Placement Agents’ fees           |     | $                                  | 0.2527 |     | $                                               | 0.2527 |     | $     |   490,014.11 |
| Proceeds, before expenses, to us |     | $                                  | 3.3573 |     | $                                               | 3.3572 |     | $     | 6,510,026.52 |

Determination of Offering Price

The offering price has been negotiated between us, the Placement Agents and the Purchaser. In determining the offering price of the securities, the following factors were considered:

| ● | prevailing                                                                                       
 market conditions;                                                                               |
| ● | our                                                                                              
 historical performance and capital structure;                                                    |
| ● | estimates                                                                                        
 of our business potential and earnings prospects;                                                |
| ● | an                                                                                               
 overall assessment of our management; and                                                        |
| ● | the                                                                                              
 consideration of these factors in relation to market valuation of companies in related business. |

| S-13 |

Lock-up Agreements

Each of our executive officers and directors has agreed, subject to certain exceptions, not to dispose of or hedge any shares of common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of the lock-up agreement continuing through the 60 days after the closing of this offering.

Securities Issuance Standstill

Pursuant to the terms of the Purchase Agreement and subject to certain exceptions, we are prohibited from entering into any agreement to issue or announcing the issuance or proposed issuance of any shares of common stock or securities convertible or exercisable into common stock for a period commencing on the date hereof and expiring 60 days from the closing date of this offering.

Furthermore, we are also prohibited from entering into any